Ratings Sabra Health Care REIT, Inc.

Equities

SBRA

US78573L1061

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
13.94 USD +2.12% Intraday chart for Sabra Health Care REIT, Inc. +2.05% -2.31%

Strengths

  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • This company will be of major interest to investors in search of a high dividend stock.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • One of the major weak points of the company is its financial situation.
  • The firm trades with high earnings multiples: 24.04 times its 2024 earnings per share.
  • Based on current prices, the company has particularly high valuation levels.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Specialized REITs

1st Jan change Capi. Investor Rating ESG Refinitiv
-2.31% 3.23B
C+
+4.62% 55.76B
A-
-11.72% 17.72B
A-
-5.05% 13.23B
A
+1.40% 7.68B
B
-16.54% 5.39B
B-
+8.62% 3.28B
C-
-5.42% 3.06B
B+
-8.15% 2.73B
C
+12.61% 2.73B
C-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SBRA Stock
  4. Ratings Sabra Health Care REIT, Inc.